Infectious Diseases Vaccine Market Overview: Key Companies & Strategies - In times of crisis, Big Pharma turns to vaccines

Long being regarded as an unattractive market, vaccines have re-emerged as successful growth driver for Big Pharma. The launch and rapid uptake of novel, high-price products such as Wyeth's Prevnar or Merck & Co's Gardasil, along with the emergence of novel vaccine technologies and favourable legislation have brought vaccines back into the main focus of pharmaceutical and biotech companies.

With the exception of influenza, only two to three vaccine manufacturers compete for each disease. This lack of competition combined with public health requirements to guarantee a stable supply of vaccines has resulted in a recent upward shift of vaccine prices for specialty vaccines.

The most significant threat to the oligopoly of the Big 5 in the vaccines market comes from companies from emerging markets, which have large manufacturing capacities for biologics and are able to produce even complex substances like vaccines at low costs.

While vaccine sales have grown at a CAGR of 32% between 2004 and 2007 and shown an annual growth rate of 46% between 2006 and 2007, overall pharmaceutical sales have grown much more slowly, with both the 2004-2007 CAGR as well as the growth rate between 2006 and 2007 only reaching 8%.

Read more...

"Infectious Diseases Vaccine Market Overview: Key Companies & Strategies" brochure is now available at Framavita.Net-Downloads

• Pain Market Overview (19/02/2010)
• Cardiovascular and metabolic market overview (20/07/2009)
• Tuberculosis (03/04/2009)

• Croatia - Pharmaceuticals and Biotechnology (18/10/2008)
• Leading Drug Delivery Companies and Technologies (14/10/2008)
• Management of Diabetes (14/10/2008)
• Obesity Drug Markets (14/10/2008)
• Valuing Pharmaceutical Innovation (14/10/2008)
• The Anti-Infectives Market Outlook to 2013 (14/10/2008)
• Respiratory Disorders (14/10/2008)
• Monoclonal Antibodies Report (14/10/2008)
• EU Pharmaceutical Forum (11/10/2008)

---